FAM230I: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: FAM230I

NCBI ID: G388882

FAM230I

Other Name(s): LOC388882 | Uncharacterized LOC388882 | family with sequence similarity 230 member I | LINC01658

FAM230I: A Potential Drug Target Or Biomarker for Various Diseases

FAM230I (LOC388882) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the FAM (fucosin-associated protein) family, which includes a variety of proteins that are involved in cellular signaling processes. One of the functions of these proteins is to modulate the expression of genes that are involved in inflammation, stress, and other processes that are important for maintaining the health and function of the body.

Recent studies have identified FAM230I as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has led to a growing interest in the research of FAM230I and its potential applications in these fields.

Disease-Related Research of FAM230I

FAM230I has been shown to be involved in a number of different diseases and disorders. One of the most significant findings related to FAM230I is its involvement in cancer. Several studies have shown that FAM230I is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, experiments have shown that inhibiting the activity of FAM230I has the potential to be a valuable therapeutic approach for cancer treatment.

Another area of research related to FAM230I is its potential as a biomarker for neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of progressive neurological symptoms. Several studies have shown that FAM230I is involved in the development and progression of these diseases, and that its activity may play a role in the development of these conditions.

FAM230I has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions involve the immune system attacking the body's own tissues, leading to inflammation and the development of joint pain and other symptoms. FAM230I has been shown to be involved in the regulation of immune responses, and its activity in these processes may be important for understanding and treating these disorders.

Potential Therapeutic Applications of FAM230I

The potential therapeutic applications of FAM230I are vast and varied. One of the most promising areas of research is the use of FAM230I as a drug target for cancer. By inhibiting the activity of FAM230I, researchers may be able to develop new treatments for a variety of cancers. Additionally, FAM230I has been shown to be involved in the regulation of inflammation and immune responses, which may make it an attractive target for therapies aimed at reducing inflammation and improving immune function.

Another potential application of FAM230I is its use as a biomarker for neurodegenerative diseases. By using FAM230I as a diagnostic marker or target for therapeutic intervention, researchers may be able to develop new treatments for these conditions. Additionally, FAM230I may be a useful target for studying the underlying molecular mechanisms that drive neurodegenerative diseases.

Conclusion

FAM230I (LOC388882) is a protein that has been shown to be involved in a variety of diseases and disorders. Its potential as a drug target or biomarker has led to a growing interest in its research and the development of new treatments for a variety of conditions. Further studies are needed to fully understand the role of FAM230I in these processes and to develop effective therapies based on its properties.

Protein Name: Family With Sequence Similarity 230 Member I

The "FAM230I Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM230I comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets